Leukemia Clinical Trials in Cleveland

Showing 581-600 of 1,477 trials

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

NCT04474613

The purpose of this study is to determine if liquid biopsies will reduce time to begin treatment in participants with non-small cell lung cancer (NSCLC). A liquid biopsy is a test done on a sample of blood to look for cancer cells.

Non Small Cell Lung Cancer

Case Comprehensive Cancer Center26 participantsStarted Aug 2020

Cleveland, Ohio, United States

TERMINATEDPhase 1< 1 mile

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

NCT04887259

A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia

Lava Therapeutics16 participantsStarted Jul 2021

Atlanta, Georgia, United States • New York, New York, United States • Charlotte, North Carolina, United States +11 more locations

Active Not RecruitingPhase 3< 1 mile

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung Cancer

Mirati Therapeutics Inc.453 participantsStarted Feb 2021

Cerritos, California, United States • Duarte, California, United States • Glendale, California, United States +340 more locations

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Leukemia Trials in Other Cities

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma

Pulmonary Rehabilitation Before Lung Cancer Resection

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

A Study of SGN-ALPV in Advanced Solid Tumors

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Bright Ideas - CIN Feasibility Study

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Other Conditions in Cleveland